Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Shareholder Meeting (November 2023)
9 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 24, 2023
Slide 1: 2023 AGM Chairman's Address and CEO Presentation
24 November 2023 2023 AGM Chairman’s Address and CEO Presentation PYC Therapeutics (ASX:PYC) (PYC or the Company) submits the following Chairman’s Address and CEO Presentation to be made at the 2023 Annual General Meeting being held today at The Harry Perkins Institute of Medical Research, at 9am AW
Slide 2: Chairman's Address
CHAIRMAN’S ADDRESS In the Annual Report which was released just a few weeks ago, I foreshadowed that important results from the Company’s fourth drug programme were imminent. Those results were announced last week and they relate to a programme to discover a treatment for Polycystic Kidney Disease (
Slide 3: Life-changing science – Annual General Meeting
For personal use only Life-changing science Annual General Meeting November 2023
Slide 4: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 5: Executive Summary – PYC Therapeutics
Executive Summary – PYC Therapeutics For personal use only A clinical-stage drug discovery & development company Creating first-in-class RNA drugs for patients with genetic diseases With a multi-asset pipeline - each program targeting commercially attractive markets ($1 to $10 billion p.a.¹) Develop
Slide 6: PYC is progressing first-in-class drugs with disease modifying potential
PYC is progressing 4 first-in-class drugs with disease modifying potential into and through clinical studies For personal use only Scale into multiple clinical 3 safety and efficacy read-outs Objectives Evolution to a clinical- 2 stage multi-asset • Establish human safety of platform company technol
Slide 7: Critical features differentiate PYC's path to revenue
3 critical features differentiate PYC’s path to revenue For personal use only DISCOVERY PRE-CLINICAL IND ENABLING CLINICAL TRIALS MARKETED Highest % success in Retinitis Pigmentosa Type 11 2 humans The highest probability Autosomal Dominant Optic Atrophy 1 High-velocity of success in the clinic¹ pat
Slide 8: PYC expects human data read-outs within the next months
PYC expects 6 human data read-outs within the next 36 months WITHIN 12 MONTHS WITHIN 24 MONTHS WITHIN 36 MONTHS For personal use only Formal safety read-out Efficacy read-outs Initiate Pivotal/Registrational trial Retinitis Pigmentosa Type 11 (Phase 1) + Efficacy insights pivotal study (Phase 3) Aut
Slide 9: PYC is progressing a pipeline of first-in-class drugs into multi-billion dollar markets
PYC is progressing a pipeline of first-in-class drugs with disease- modifying potential into multi-billion dollar markets Historical progress Progress expected within 12 months For personal use only DISCOVERY PRE-CLINICAL IND ENABLING CLINICAL TRIALS MARKETED MARKET SIZE^ Retinitis Pigmentosa Type 1
PYC Therapeutics — Shareholder Meeting (November 2023) on 6ix